Navigation Links
Wrinkle Fillers Need Better Label Warnings: FDA Panel
Date:11/18/2008

Reports of allergic reactions, other problems have surfaced with these products, experts say

TUESDAY, Nov. 18 (HealthDay News) - American women who turn to cosmetic treatments called dermal fillers to ease wrinkles must be better informed as to the health risks these products pose, an advisory panel to the U.S. Food and Drug Administration recommended Tuesday.

The panel of independent experts urged the agency to revise product labeling to warn of potential reactions to the fillers, including bumps, blotching and scarring.

While side effects are relatively rare, the U.S. Food and Drug Administration has also received reports of allergic reactions, including some that were life-threatening, such as anaphylactic shock, the agency said.

"The labeling should be modified to reflect what we're learning further about the products'' in various post-marketing studies and elsewhere, panel member Mary McGrath, a professor of surgery at the University of California in San Francisco, told Bloomberg News.

According to the American Society for Aesthetic Plastic Surgery, nearly 1,449,000 procedures involving fillers were performed in the United States last year.

The FDA is not bound to follow the recommendations of its advisory panels, although it typically does so. As part of their review, the group reviewed a variety of reports to see if stronger warning labels were needed for the injectable products. Some fillers are made from natural substances, while others come from synthetic materials. Brand names for some of these products include Restylane, Juvederm, Artefill, and Perlane.

The FDA has also asked the panel to make recommendations on testing the dermal fillers, post-approval follow-up and informing consumers about potential risks. The meeting was spurred by reports of 823 injuries caused by dermal fillers that included allergic reactions, swelling, sores, pain, blisters and cysts.

Overall, 638 patients needed additional medical treatment. Nineteen patients were seen in emergency rooms with life-threatening allergic reactions, such as difficulty breathing. Twelve patients had to be admitted to hospitals due to infections, the FDA said.

Medications used to treat problems ranged from topical steroid creams to multiple courses of oral antibiotics, topical steroids, anti-inflammatory or antihistamine drugs, and intra-lesion steroid injections. Ninety-four of the 823 reported injuries required surgical intervention, ranging from opening an abscess for drainage of pus, to biopsy of lesions, the FDA said.

One of the FDA's concerns is that some of the products are being used in ways that they weren't approved for -- called "off-label use."

"The trouble is that once this material is in the hands of physicians, there's really not much control over how it's used and where it's placed," Dr. Scott Spear, a Washington plastic surgeon., told the AP. "That creates the potential for a certain amount of mischief."

There's limited data on how darker-skinned people may react to the dermal filler treatments. Hispanic, black and Asian patients may develop blotches and other complications, the FDA said.

"Off-label" use of these products may be the cause of some of these problems. Lip enhancement is a common off-label use, the FDA said.

Another concern is what happens to the fillers as they break down and circulate throughout the body. Most of the products appear to cause no problems, but one contains small plastic balls that aren't absorbed by the body, the FDA has noted.

More information

For more on cosmetic surgery, visit the American Society of Plastic Surgeons.



SOURCE: U.S. Food and Drug Administration; Nov. 18, 2008, Associated Press, Bloomberg News


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Cougars Crave Biocap, The Haute Pepper Wrinkle Eraser
2. New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
3. Botox Cosmetic Alternatives Are Available: Surgical Procedures Offer Solution for Wrinkles
4. FDA Grants Over-The-Counter Clearance to GentleWaves(R) for the First Home Use Light-Based Device to Treat Wrinkles
5. GFX: Wrinkle-Killer or Botox(R) Hit-Man?
6. Grassini & Wrinkle Law Firm Are Awarded Largest PI Verdict in Ventura County History
7. New Medical Technology is Changing the Face of Wrinkle Treatment
8. Another new wrinkle in treating skin aging
9. Clinical Trial Concluded For New Wrinkle Treatment
10. FDA Takes Closer Look at Wrinkle Treatments
11. Dr. Arnold Klein Warns of Dangers With Permanent and Longer Lasting Injectable Fillers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Wrinkle Fillers Need Better Label Warnings: FDA Panel
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. ... will be included in the 2016 “Guide to America’s Top Plastic Surgeons” for ... the amalgamation of their education, experience, and professional associations. , One the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... diagnostic imaging systems and the first company to offer robotic imaging to ... at their tradeshow booth # 941 for the American Association of Equine Practitioners ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... announce that we have been designated as a Cigna Infertility Center of Excellence. ... rigorous performance standards. , “It’s an honor to be designated a Cigna ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Research and Markets has announced the addition of ... Markets and Companies" to their offering. ... , , ... The market value of drug delivery technologies and the anticancer drugs ... according to organs involved and the types of cancer as well ...
(Date:12/2/2016)... Conn. , Dec. 1, 2016  Today, Simpson ... announced the honor of being selected as winners of ... Simpson Healthcare Executives Website at the PLATINUM level, Blue ... Training Module at the GOLD Level, and our proprietary ... At Simpson Healthcare Executives, we are excited to ...
(Date:12/2/2016)... Dec. 2, 2016  UCB is pleased to announce that 12 ... upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ... TX , USA. 1-12 Data ... profile of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... on the current state of the union of epilepsy care ...
Breaking Medicine Technology: